» Articles » PMID: 32125431

Risk Factors for Severe Cranial Ischaemic Complications in Giant Cell Arteritis

Overview
Specialty Rheumatology
Date 2020 Mar 4
PMID 32125431
Citations 8
Authors
Affiliations
Soon will be listed here.
Abstract

Objectives: Vision complications and a stroke represent severe cranial ischaemic complications (sCIC) associated with increased morbidity and mortality in GCA. We aimed to determine the risk factors for sCIC in GCA.

Methods: We analysed the medical records of prospectively enrolled GCA patients diagnosed between September 2011 and August 2019, and compared the clinical and laboratory characteristics of patients with and without sCIC defined as either severe vision complications (diplopia, transient vision loss, permanent partial vision field/acuity defect and permanent visual loss) or stroke.

Results: During the 96-month observation period, we identified 295 new GCA patients [65.4% female, median (interquartile range) age 74.7 (67.3-80.0) years]. Sixty-one (20.7%) patients developed sCIC (52 isolated severe vision complications, 5 isolated ischaemic strokes and 4 patients with both complications). In a multivariable logistic regression model jaw claudication [odds ratio (OR) 3.43 (95% CI: 1.84, 6.42), P < 0.001], smoking [OR 1.92 (95% CI: 1.01, 3.65), P = 0.046] and increasing age [OR 1.08 (95% CI: 1.04, 1.13), P < 0.001] were significantly associated with sCIC. Higher CRP [OR 0.99 (0.99-1.00), P = 0.011] decreased the risk of sCIC. When considered separately, the odds for severe vision complications increased with age and jaw claudication, and decreased with polymyalgia rheumatica, constitutional symptoms and higher CRP. Atrial fibrillation emerged as the sole independent predictor of ischaemic stroke.

Conclusion: Increasing age, jaw claudication and smoking predicted sCIC, while higher CRP decreased the risk of sCIC in our GCA cohort.

Citing Articles

Risk Factors and Pharmacological Interventions Impacting Cerebrovascular Ischemic Events in Giant Cell Arteritis: A Narrative Review.

Siddiqui M, Syed M, Qureshi A, Imam M, Motwani J, Kumari V Immun Inflamm Dis. 2025; 13(1):e70122.

PMID: 39817601 PMC: 11736630. DOI: 10.1002/iid3.70122.


Jaw claudication and jaw stiffness in giant cell arteritis: secondary analysis of a qualitative research dataset.

Lim J, Dures E, Bailey L, Almeida C, Ruediger C, Hill C Rheumatol Adv Pract. 2023; 8(1):rkad082.

PMID: 38152390 PMC: 10751230. DOI: 10.1093/rap/rkad082.


Giant-cell arteritis related strokes: scoping review of mechanisms and rethinking treatment strategy?.

Bonnan M, Debeugny S Front Neurol. 2023; 14:1305093.

PMID: 38130834 PMC: 10733536. DOI: 10.3389/fneur.2023.1305093.


Giant cell arteritis-related cerebrovascular ischemic events: a French retrospective study of 271 patients, systematic review of the literature and meta-analysis.

Penet T, Lambert M, Baillet C, Outteryck O, Henon H, Morell-Dubois S Arthritis Res Ther. 2023; 25(1):116.

PMID: 37420252 PMC: 10326952. DOI: 10.1186/s13075-023-03091-x.


Long delay from symptom onset to first consultation contributes to permanent vision loss in patients with giant cell arteritis: a cohort study.

Hemmig A, Aschwanden M, Seiler S, Berger C, Kohn P, Kyburz D RMD Open. 2023; 9(1).

PMID: 36635003 PMC: 9843209. DOI: 10.1136/rmdopen-2022-002866.